Background
• Cancer : frequent secondary progression, resistance to conventional chemotherapy : therapeutic challenge
• Selection for genetic alterations during treatment • Subclonal driver mutations might play a role in tumor progression • Presence of driver mutation-harboring subclones at diagnosis, which might expand at relapse, has been linked to adverse outcome in hematological malignancies (Landau et al, 2013) • Different models of clonal evolution (Ding et al, 2011) : -Dominant clone evolves into relapse clone -A minor clone carrying the vast majority of primary tumor mutations escapes and expands at relapse • Report of a relapse-specific ALK mutation (Martinsson et al, 2011) • Objectives of this study : Determine the frequency of ALK mutations at relapse and their role in clonal evolution of NB 
